Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NASDAQ:BYSI NASDAQ:GALT NASDAQ:HELP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.51+2.2%$2.69$1.65▼$4.00$254.94M1.59304,842 shs36,716 shsBYSIBeyondSpring$1.65+2.8%$1.59$1.18▼$2.62$67.64M0.4316,269 shs17,075 shsGALTGalectin Therapeutics$4.55+7.6%$2.50$2.03▼$7.13$299.66M0.47391,308 shs218,947 shsHELPCybin$6.34+5.4%$4.84$3.76▼$9.83$325.02M0.74960,597 shs865,682 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-3.54%+2.08%-16.38%-9.26%+18.36%BYSIBeyondSpring-0.99%-0.62%+3.90%0.00%-36.25%GALTGalectin Therapeutics+7.91%+49.47%+51.61%+57.84%+68.53%HELPCybin+18.27%+28.91%+35.89%+33.19%+601,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.51+2.2%$2.69$1.65▼$4.00$254.94M1.59304,842 shs36,716 shsBYSIBeyondSpring$1.65+2.8%$1.59$1.18▼$2.62$67.64M0.4316,269 shs17,075 shsGALTGalectin Therapeutics$4.55+7.6%$2.50$2.03▼$7.13$299.66M0.47391,308 shs218,947 shsHELPCybin$6.34+5.4%$4.84$3.76▼$9.83$325.02M0.74960,597 shs865,682 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-3.54%+2.08%-16.38%-9.26%+18.36%BYSIBeyondSpring-0.99%-0.62%+3.90%0.00%-36.25%GALTGalectin Therapeutics+7.91%+49.47%+51.61%+57.84%+68.53%HELPCybin+18.27%+28.91%+35.89%+33.19%+601,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 2.25Hold$7.50206.12% UpsideBYSIBeyondSpring 1.00SellN/AN/AGALTGalectin Therapeutics 2.00Hold$11.00160.05% UpsideHELPCybin 3.00Buy$58.75875.91% UpsideCurrent Analyst Ratings BreakdownLatest BYSI, HELP, ACIU, and GALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026GALTGalectin Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.006/18/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026ACIUAC Immune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/4/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/4/2026ACIUAC Immune BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/21/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ACIUAC Immune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026HELPCybin TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy3/27/2026BYSIBeyondSpring Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$3.70M67.35N/AN/A$0.54 per share4.54BYSIBeyondSpring$1.75M37.60$0.11 per share14.48($0.59) per share-2.71GALTGalectin TherapeuticsN/AN/AN/AN/A($1.99) per shareN/AHELPCybinN/AN/AN/AN/A$7.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$85.03M-$0.82N/A14.41N/A-1,788.02%-125.26%-40.85%8/4/2026 (Estimated)BYSIBeyondSpring-$1.01M-$0.14N/AN/AN/AN/AN/A-14.00%8/12/2026 (Estimated)GALTGalectin Therapeutics-$30.84M-$0.41N/AN/AN/AN/AN/A-164.69%8/13/2026 (Estimated)HELPCybin-$81.31M-$4.23N/AN/AN/AN/A-59.98%-50.80%N/ALatest BYSI, HELP, ACIU, and GALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026GALTGalectin Therapeutics-$0.06-$0.08-$0.02-$0.08N/AN/A5/13/2026Q4 2025BYSIBeyondSpring-$0.54-$0.05+$0.49-$0.05$8.77 millionN/A4/30/2026Q1 2026ACIUAC Immune-$0.20-$0.19+$0.01-$0.19$0.33 million$1.40 million3/31/2026Q4 2025GALTGalectin Therapeutics-$0.10-$0.08+$0.02-$0.08$36.32 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/AHELPCybinN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC Immune0.110.871.02BYSIBeyondSpringN/A1.091.09GALTGalectin TherapeuticsN/A2.152.15HELPCybinN/A13.7813.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%BYSIBeyondSpring40.29%GALTGalectin Therapeutics11.68%HELPCybin17.94%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%BYSIBeyondSpring29.31%GALTGalectin Therapeutics52.60%HELPCybin15.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140101.77 million97.09 millionOptionableBYSIBeyondSpring8041.12 million29.07 millionOptionableGALTGalectin Therapeutics965.86 million31.22 millionOptionableHELPCybin5051.63 million43.89 millionN/ABYSI, HELP, ACIU, and GALT HeadlinesRecent News About These CompaniesCybin (NASDAQ:HELP) Trading 18.3% Higher - What's Next?June 26 at 2:21 AM | americanbankingnews.comHelus Pharma Raises US$50 Million to Advance Late-Stage Mental Health Drug PipelineJune 25 at 11:31 AM | tipranks.comHelus Pharma™ Announces Closing of US$50 Million Underwritten OfferingJune 25 at 9:27 AM | globenewswire.comHelus Pharma™ Announces US$50 Million Underwritten OfferingJune 24 at 6:01 AM | globenewswire.comHelus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment ProgressJune 24 at 6:00 AM | globenewswire.comHelus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives ConferenceJune 11, 2026 | globenewswire.comHelus Pharma to Participate in the Jefferies Global Healthcare Conference in New YorkJune 1, 2026 | globenewswire.comCORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental HealthApril 30, 2026 | globenewswire.comHelus Pharma to Participate at the 29th Annual Milken Institute Global ConferenceApril 30, 2026 | globenewswire.comHelus Pharma Partners with TARA Mind to Advance Veteran Mental HealthApril 28, 2026 | globenewswire.comDoes Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk?April 25, 2026 | finance.yahoo.comHelus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen BrannanApril 23, 2026 | globenewswire.comCybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade)April 22, 2026 | seekingalpha.comPsychedelic drug stocks soar as Trump fast‑tracks FDA reviewsApril 20, 2026 | usatoday.comHow Trump's psychedelics executive order could unlock stalled cannabis reformApril 20, 2026 | cnbc.comPsychedelic stocks rally after Trump orders faster PTSD research; Compass Pathways, Atai lead gainsApril 20, 2026 | msn.comCybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD researchApril 20, 2026 | msn.comHelus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health ConditionsApril 20, 2026 | globenewswire.comHelus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive OfficerApril 20, 2026 | globenewswire.comCybin Insider Ups Holding By 105% During YearApril 19, 2026 | finance.yahoo.comMagic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise (HELP)...February 20, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap SpaceBy Nathan Reiff | June 14, 2026These 3 CLO ETFs Target a Niche Corner of the Fixed-Income MarketBy Nathan Reiff | May 31, 20263 Inflation-Fighting Stocks Built for Higher Oil PricesBy Thomas Hughes | June 21, 2026ERock IPO: A $1.3B Power Play SolutionBy Jeffrey Neal Johnson | June 12, 2026Why 1 Little-Known ETF Is Riding the AI Chip ShortageBy Nathan Reiff | June 2, 2026BYSI, HELP, ACIU, and GALT Company DescriptionsAC Immune NASDAQ:ACIU$2.50 +0.06 (+2.24%) As of 11:08 AM Eastern This is a fair market value price provided by Massive. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.BeyondSpring NASDAQ:BYSI$1.64 +0.05 (+2.81%) As of 11:09 AM Eastern This is a fair market value price provided by Massive. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Galectin Therapeutics NASDAQ:GALT$4.55 +0.32 (+7.57%) As of 10:51 AM EasternGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Cybin NASDAQ:HELP$6.34 +0.32 (+5.37%) As of 11:09 AM Eastern This is a fair market value price provided by Massive. Learn more.Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal MDA Space Targets US Defense Market With $620M Acquisition Qualcomm’s $4B AI Deal Takes Aim at NVIDIA’s Software Moat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
